NASDAQ:RLAY Relay Therapeutics (RLAY) Stock Price, News & Analysis $6.24 -0.25 (-3.85%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$6.21▼$6.8350-Day Range$6.24▼$9.4852-Week Range$5.70▼$12.14Volume803,792 shsAverage Volume1.17 million shsMarket Capitalization$828.31 millionP/E RatioN/ADividend YieldN/APrice Target$21.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Relay Therapeutics alerts: Email Address Relay Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside247.2% Upside$21.67 Price TargetShort InterestBearish6.82% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$715,499 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.91) to ($3.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.07 out of 5 starsMedical Sector615th out of 909 stocksBiological Products, Except Diagnostic Industry96th out of 154 stocks 4.5 Analyst's Opinion Consensus RatingRelay Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRelay Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Relay Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.82% of the outstanding shares of Relay Therapeutics have been sold short.Short Interest Ratio / Days to CoverRelay Therapeutics has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Relay Therapeutics has recently increased by 2.61%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRelay Therapeutics does not currently pay a dividend.Dividend GrowthRelay Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RLAY. Previous Next 1.1 News and Social Media Coverage News SentimentRelay Therapeutics has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Relay Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for RLAY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Relay Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Relay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $715,499.00 in company stock.Percentage Held by InsidersOnly 4.32% of the stock of Relay Therapeutics is held by insiders.Percentage Held by Institutions96.98% of the stock of Relay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Relay Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Relay Therapeutics are expected to decrease in the coming year, from ($2.91) to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relay Therapeutics is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relay Therapeutics is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelay Therapeutics has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Relay Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Gold RepublicChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . Click here now to get your free 'De-Dollarization' Guide. About Relay Therapeutics Stock (NASDAQ:RLAY)Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More RLAY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RLAY Stock News HeadlinesSeptember 6 at 4:05 PM | globenewswire.comRelay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024August 8, 2024 | finanznachrichten.deRelay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate HighlightsSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 6, 2024 | msn.comRelay Therapeutics GAAP EPS of -$0.69 beats by $0.04August 6, 2024 | globenewswire.comRelay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate HighlightsJuly 24, 2024 | finance.yahoo.comWe're Not Very Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn RateJune 24, 2024 | seekingalpha.comRelay Therapeutics: A 'Concept' StockJune 6, 2024 | globenewswire.comRelay Therapeutics Discloses Three New Programs at New Program & Platform EventSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.June 5, 2024 | globenewswire.comRelay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608May 21, 2024 | globenewswire.comRelay Therapeutics to Participate in Upcoming Investor ConferencesMay 13, 2024 | globenewswire.comRelay Therapeutics to Host New Program and Platform Event on June 6, 2024May 10, 2024 | msn.comRelay Therapeutics upgraded by Barclays ahead of data readoutMay 10, 2024 | msn.comBarclays Upgrades Relay Therapeutics (RLAY)May 8, 2024 | markets.businessinsider.comOptimistic Buy Rating for Relay Therapeutics: Pipeline Progress and Financial Stability Drive Analyst ConfidenceMay 4, 2024 | finance.yahoo.comRelay Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 2, 2024 | finance.yahoo.comRelay Therapeutics Outperforms Revenue Expectations in Q1 2024May 2, 2024 | investorplace.comRLAY Stock Earnings: Relay Therapeutics Beats EPS, Beats Revenue for Q1 2024See More Headlines Receive RLAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RLAY CUSIPN/A CIK1812364 Webwww.relaytx.com Phone617-370-8837FaxN/AEmployees330Year FoundedN/APrice Target and Rating Average Stock Price Target$21.67 High Stock Price Target$30.00 Low Stock Price Target$14.00 Potential Upside/Downside+247.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-341,970,000.00 Net MarginsN/A Pretax Margin-916.89% Return on Equity-43.66% Return on Assets-38.38% Debt Debt-to-Equity RatioN/A Current Ratio15.64 Quick Ratio15.64 Sales & Book Value Annual Sales$35.21 million Price / Sales23.53 Cash FlowN/A Price / Cash FlowN/A Book Value$5.90 per share Price / Book1.06Miscellaneous Outstanding Shares132,742,000Free Float127,008,000Market Cap$828.31 million OptionableOptionable Beta1.64 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Alexis A. Borisy A.M. (Age 52)Co-Founder & Independent Chairman Comp: $92.5kDr. Sanjiv K. Patel M.A. (Age 50)M.B.A., M.D., MBBS, CEO, President & Director Comp: $1.08MDr. Mark Murcko Ph.D. (Age 64)Co-Founder & Director Comp: $60kMr. Thomas Catinazzo (Age 47)Chief Financial Officer Comp: $663.99kMr. Brian R. Adams J.D. (Age 50)Chief Legal Officer & Secretary Comp: $627.72kMr. Peter RahmerChief Corporate Development OfficerDr. Donald A. Bergstrom M.D. (Age 52)Ph.D., President of Research & Development Comp: $1.37MDr. Deborah Palestrant M.B.A.Ph.D., Vice President of Corporate Development & StrategyMr. Jim Watters Ph.D.Chief Scientific Officer of Late ResearchDr. Beni B. Wolf M.D.Ph.D., Chief Medical Officer & Head of Precision MedicineMore ExecutivesKey CompetitorsVir BiotechnologyNASDAQ:VIRAllogene TherapeuticsNASDAQ:ALLOFate TherapeuticsNASDAQ:FATEFive Prime TherapeuticsNASDAQ:FPRXIDEAYA BiosciencesNASDAQ:IDYAView All CompetitorsInsiders & InstitutionsDriehaus Capital Management LLCBought 218,302 shares on 8/16/2024Ownership: 0.460%Algert Global LLCBought 174,953 shares on 8/16/2024Ownership: 0.356%The Manufacturers Life Insurance Company Sold 19,598 shares on 8/15/2024Ownership: 0.161%Caxton Associates LPSold 23,248 shares on 8/15/2024Ownership: 0.080%Susquehanna Fundamental Investments LLCBought 38,117 shares on 8/15/2024Ownership: 0.040%View All Insider TransactionsView All Institutional Transactions RLAY Stock Analysis - Frequently Asked Questions How have RLAY shares performed this year? Relay Therapeutics' stock was trading at $11.01 on January 1st, 2024. Since then, RLAY shares have decreased by 43.3% and is now trading at $6.24. View the best growth stocks for 2024 here. How were Relay Therapeutics' earnings last quarter? Relay Therapeutics, Inc. (NASDAQ:RLAY) issued its earnings results on Tuesday, August, 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.04. When did Relay Therapeutics IPO? Relay Therapeutics (RLAY) raised $250 million in an initial public offering (IPO) on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO. Who are Relay Therapeutics' major shareholders? Top institutional investors of Relay Therapeutics include Dimensional Fund Advisors LP (1.15%), Logos Global Management LP (0.98%), Millennium Management LLC (0.86%) and Renaissance Technologies LLC (0.68%). Insiders that own company stock include Mark Murcko, Sanjiv Patel, Donald A Bergstrom, Peter Rahmer, Thomas Catinazzo, Brian Adams and Andy Porter. View institutional ownership trends. How do I buy shares of Relay Therapeutics? Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Relay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Relay Therapeutics investors own include Beyond Meat (BYND), CureVac (CVAC), QuidelOrtho (QDEL), Teladoc Health (TDOC), Tesla (TSLA), Datadog (DDOG) and DraftKings (DKNG). This page (NASDAQ:RLAY) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredThese 2 simple sentences turn every Friday into payday?Most people have never heard of Jim Fink. Behind his humble demeanor and insistence on personal privacy... ...Investing Daily | SponsoredHere’s A Painful Truth and 100% Fact About The Stocks You’re HoldingCharles Payne here, and I want to let you in on an uncomfortable truth that long term investors and retirees n...Unstoppable Prosperity | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLAY Stock Alerts